Распространенность депрессивных расстройств и их роль в формировании различных вариантов патологии человека обусловливают актуальность поиска новых подходов к ...профилактике и лечению депрессий. Перспективным направлением может стать модификация микробиома кишечника. Основанием для разработок в этой области являются приведенные в обзоре данные исследований, подтверждающих значимость состава кишечной флоры в регуляции психических функций, в частности настроения и поведения, роль диеты в развитии депрессий. Обсуждена гипотеза о роли микробиома кишечника в развитии депрессивных расстройств. http://www.ssmj.ru/system/files/2016_02_168-174.pdf
more
Brief review of selected topics
The following pages provide a focus on selected areas in relation to neurology. The specialists who contributed the reviews are listed in the Project Team and Partners
Neurology Atlas (2004)
Includes a Special Report on the Financial and Personal Benefits of Early Diagnosis
2018 Alzheimer’s Disease Facts and Figures is a statistical resource for U.S. data related to Alzheimer’s disease,
the most common cause of dementia. Background and context for interpretating the data are con...tained in
the Overview. Additional sections address prevalence, mortality and morbidity, caregiving and use and costs of health care and services. A Special Report discusses the financial and personal benefits of diagnosing earlier in the disease process, in the stage of mild cognitive impairment.
more
Received Date: Jun 15, 2017; Accepted Date: Jun 28, 2017; Published Date: Jun 30, 2017
Citation: Etindele Sosso FA, Nakamura O, Nakamura M (2017) Epidemiology of Alzheimer’s Disease: Comparison between Africa and South America. J Neurol Neurosci Vol.8 No.4:204. DOI: 10.21767/2171-6625.1000204
20 February 2013
Update on 2004 Background Paper (Written by Saloni Tanna)
Priority Medicines for Europe and the World "A Public Health Approach to Innovation"
The International Association for Child and Adolescent Psychiatry and
Allied Professions (IACAPAP) aims to promote the mental health and
development of children and adolescents worldwide. It seeks to achieve
this by contributing to the training and professional development of the
child and adole...scent mental health professionals by disseminating up-todate
and high-quality information through its publications, organization
of biennial international congresses, and study groups. IACAPAP has a
long tradition of publishing monographs released to coincide with the
congresses, with the first one published in 1970.
more
Q10: For carers of people with dementia, does respite care when compared to care as usual, produce benefits/harm in the specified outcomes?
mhGAP Training Manual for the mhGAP Intervention Guide for mental, neurological and substance use disorders in non-specialized health settings – version 2.0 (for field testing)
Accessed 06.03.2019
Q5: For people with dementia, which cognitive/psychosocial interventions (such as cognitive stimulation, cognitive rehabilitation, reality orientation, reminiscence therapy) when compared to placebo/comparator produce benefits/harm in the specified outcomes?
Q6: Can dementia be diagnosed at first or second level care by non-specialist health care providers? What should be the assessment process for the diagnosis of dementia?
The report “Dementia: a public health priority” has been jointly developed by WHO and Alzheimer's Disease International. The purpose of this report is to raise awareness of dementia as a public health priority, to articulate a public health approach and to advocate for action at international a...nd national levels.
Dementia is a syndrome that affects memory, thinking, behaviour and ability to perform everyday activities. The number of people living with dementia worldwide is currently estimated at 35.6 million. This number will double by 2030 and more than triple by 2050. Dementia is overwhelming not only for the people who have it, but also for their caregivers and families. There is lack of awareness and understanding of dementia in most countries, resulting in stigmatization, barriers to diagnosis and care, and impacting caregivers, families and societies physically, psychologically and economically.
Available Languages: Chinese, English, Japanese, Russian and Spanish
more
Progress towards targets of the Global action plan on dementia
Q6: What is the added advantage of doing neuroimaging in people with convulsive epilepsy in non-specialist settings in low and middle income countries?
Q5: What is the added advantage of doing an electroencephalography (EEG) in people with convulsive epilepsy in non- specialist settings in low and middle income countries?
Q8. Should Anti-Epileptic Drug (AED) treatment be started after first unprovoked seizure in non-specialist health settings?
Q4: Can convulsive epilepsy be diagnosed at first level care by a non-specialist health care provider in low and middle income country settings?
SCOPING QUESTION: In adults with acute convulsive seizures, where intravenous access is available, which first-line anti- epileptic medication should be used to abort seizures when compared to comparator?
[Updated 2015]
Scoping Question: In adults with acute convulsive seizures in first-level care or in the community (when no IV access is available), which antiepileptic medications produce benefits and/or harm when compared to comparator?
SCOPING QUESTION: For adults and children with medication-resistant convulsive epilepsy, which anti-epileptic medications produce benefits and/or harm in the specified outcomes when compared to a placebo or a comparator?